These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 38038064)

  • 21. Morphometry of SARS-CoV and SARS-CoV-2 particles in ultrathin plastic sections of infected Vero cell cultures.
    Laue M; Kauter A; Hoffmann T; Möller L; Michel J; Nitsche A
    Sci Rep; 2021 Feb; 11(1):3515. PubMed ID: 33568700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Static all-atom energetic mappings of the SARS-Cov-2 spike protein and dynamic stability analysis of "Up" versus "Down" protomer states.
    Peters MH; Bastidas O; Kokron DS; Henze CE
    PLoS One; 2020; 15(11):e0241168. PubMed ID: 33170884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2: preliminary study of infected human nasopharyngeal tissue by high resolution microscopy.
    Mondeja B; Valdes O; Resik S; Vizcaino A; Acosta E; Montalván A; Paez A; Mune M; Rodríguez R; Valdés J; Gonzalez G; Sanchez D; Falcón V; González Y; Kourí V; ; Díaz A; Guzmán M
    Virol J; 2021 Jul; 18(1):149. PubMed ID: 34275492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection.
    Messina F; Giombini E; Agrati C; Vairo F; Ascoli Bartoli T; Al Moghazi S; Piacentini M; Locatelli F; Kobinger G; Maeurer M; Zumla A; Capobianchi MR; Lauria FN; Ippolito G;
    J Transl Med; 2020 Jun; 18(1):233. PubMed ID: 32522207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Supramolecular Organization of SARS-CoV and SARS-CoV-2 Virions Revealed by Coarse-Grained Models of Intact Virus Envelopes.
    Wang B; Zhong C; Tieleman DP
    J Chem Inf Model; 2022 Jan; 62(1):176-186. PubMed ID: 34911299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human Surfactant Protein D Binds Spike Protein and Acts as an Entry Inhibitor of SARS-CoV-2 Pseudotyped Viral Particles.
    Hsieh MH; Beirag N; Murugaiah V; Chou YC; Kuo WS; Kao HF; Madan T; Kishore U; Wang JY
    Front Immunol; 2021; 12():641360. PubMed ID: 34054808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Taxonium, a web-based tool for exploring large phylogenetic trees.
    Sanderson T
    Elife; 2022 Nov; 11():. PubMed ID: 36377483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RG203KR Mutations in SARS-CoV-2 Nucleocapsid: Assessing the Impact Using a Virus-Like Particle Model System.
    Raheja H; Das S; Banerjee A; P D; C D; Mukhopadhyay D; Ramachandra SG; Das S
    Microbiol Spectr; 2022 Aug; 10(4):e0078122. PubMed ID: 35862952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 Spike Protein Interaction Space.
    Lungu CN; Putz MV
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles.
    Plescia CB; David EA; Patra D; Sengupta R; Amiar S; Su Y; Stahelin RV
    J Biol Chem; 2021; 296():100103. PubMed ID: 33214224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimum Sizes of Respiratory Particles Carrying SARS-CoV-2 and the Possibility of Aerosol Generation.
    Lee BU
    Int J Environ Res Public Health; 2020 Sep; 17(19):. PubMed ID: 32977575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomolecular assay based on selective virion capture by spike antibody and viral nucleic acid amplification for detecting intact SARS-CoV-2 particles.
    Wu X; Liu J; Zhang H; Zhou H; Wang W; Ma Y; Shen S; Cai X; Huang A; Wang D
    J Nanobiotechnology; 2022 Sep; 20(1):399. PubMed ID: 36064407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensive care for seriously ill patients affected by novel coronavirus sars - CoV - 2: Experience of the Crema Hospital, Italy.
    Zuccon W; Comassi P; Adriani L; Bergamaschini G; Bertin E; Borromeo R; Corti S; De Petri F; Dolci F; Galmozzi A; Gigliotti A; Gualdoni L; Guerra C; Khosthiova A; Leati G; Lupi G; Moscato P; Perotti V; Piantelli M; Ruini A; Sportelli S; Susca M; Troiano C; Benelli G; Buscarini E; Canetta C; Merli G; Scartabellati A; Melilli B S C G; Sfogliarini R; Pellegatta G; Viganò G
    Am J Emerg Med; 2021 Jul; 45():156-161. PubMed ID: 33046317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 Proteins: Are They Useful as Targets for COVID-19 Drugs and Vaccines?
    Mohammed MEA
    Curr Mol Med; 2022; 22(1):50-66. PubMed ID: 33622224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mammalian cells-based platforms for the generation of SARS-CoV-2 virus-like particles.
    Elfayres G; Paswan RR; Sika L; Girard MP; Khalfi S; Letanneur C; Milette K; Singh A; Kobinger G; Berthoux L
    J Virol Methods; 2023 Dec; 322():114835. PubMed ID: 37871706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultrastructural modifications induced by SARS-CoV-2 in Vero cells: a kinetic analysis of viral factory formation, viral particle morphogenesis and virion release.
    Eymieux S; Rouillé Y; Terrier O; Seron K; Blanchard E; Rosa-Calatrava M; Dubuisson J; Belouzard S; Roingeard P
    Cell Mol Life Sci; 2021 Apr; 78(7):3565-3576. PubMed ID: 33449149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Presumed SARS-CoV-2 Viral Particles in the Human Retina of Patients With COVID-19.
    Araujo-Silva CA; Marcos AAA; Marinho PM; Branco AMC; Roque A; Romano AC; Matuoka ML; Farah M; Burnier M; Moraes NF; Tierno PFGMM; Schor P; Sakamoto V; Nascimento H; de Sousa W; Belfort R
    JAMA Ophthalmol; 2021 Sep; 139(9):1015-1021. PubMed ID: 34323931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The size distribution of SARS-CoV-2 genetic material in airborne particles sampled in hospital and home care environments occupied by COVID-19 positive subjects.
    Cvitešić Kušan A; Baranašić J; Frka S; Lucijanić T; Šribar A; Knežević J; Buonanno G; Stabile L
    Sci Total Environ; 2023 Sep; 892():164642. PubMed ID: 37271394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.